Navigation Links
Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
Date:3/19/2009

future.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the future of Valeant's business and performance. These statements are based upon the current expectations and beliefs of Valeant's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to Valeant's ability to successfully integrate its acquisitions and to realize the benefits of these acquisitions and management's ability to improve operations, as well as other risks and uncertainties discussed in the company's filings with the SEC. The company cautions the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. The company also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this press release. The company undertakes no responsibility to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
<
'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 Victory Healthcare, a ... 2014 third quarter infection rates and patient satisfaction ... rates of only two percent or less, and ... exceeding 98 percent. , “We are delighted with ... rising satisfaction scores,” said Robert Helms, chairman and ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Scientists who used ... laboratory say their breakthrough could provide a new way ... stomach diseases. The team used human pluripotent stem ... in the body -- to grow the functional miniature ... bacteria, a major cause of ulcers and stomach cancer. ...
(Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
(Date:10/30/2014)... (HealthDay News) -- A new vaccine that could help ... approved by the U.S. Food and Drug Administration on ... the ages of 10 and 25 from invasive meningococcal ... bacteria. The bacteria can infect the bloodstream (sepsis) ... brain. It is a leading cause of bacterial meningitis, ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
Breaking Medicine News(10 mins):Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Gentle caffeine boost for premature babies 2
... during and after treatment resulted in less fatigue, greater ... - Exercise during and after treatment improves quality of ... or prostate cancer, a new study finds. , "Using ... potential to benefit patients both physically and psychologically, as ...
... ... 7,000 stores in under five months of operation. The site offers 30,000 coupons from 7,000 ... 500 votes per day, making it one of the fastest growing coupons/deals sites ever. ... (PRWEB) May 27, 2010 ...
... , THURSDAY, May 27 (HealthDay News) -- A new ... that many people don,t know enough about sun damage ... survey showed that despite our repeated warnings about the ... sun protection, many people could not correctly answer true/false ...
... ... and published by Random House Mondadori this ,practical guide teaches Latina women how to ... ... Guía Para Vestir Mejor (Discover Your Style: Your Guide to Dressing Better) written ...
... "color-coded" laboratory mice are providing researchers with a novel ... monitor the cellular immune responses of transplanted tissue in ... the June issue of Nature Medicine , which ... a key consideration in developing strategies to improve transplant ...
... at the UCLA Medical Center found that antiviral therapy ... is the most cost-effective approach to treating patients with ... Full details appear in the June issue of ... behalf of the American Association for the Study of ...
Cached Medicine News:Health News:Exercise Boosts Health of Cancer Patients 2Health News:Coupon Site TrimBack.com Adds 7000th Online Store 2Health News:Many People Still Don't Know How to Protect Against Skin Cancer 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 2Health News:"Descubre Tu Estilo: Tu Gua Para Vestir Mejor" Wins Triple Crown Award and Honors at the 12th International Latino Book Awards 3Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 2Health News:Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue 3Health News:Antiviral therapy during compensated cirrhosis most cost-effective approach 2
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
(Date:10/30/2014)... 2014  TWi Pharmaceuticals, Inc. today announced that it ... and Drug Administration (FDA) on its Abbreviated New Drug ... the generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® ... TWi Pharmaceuticals is preparing to launch the product ... Pharmaceuticals USA , at the earliest ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... CITY, Md., Oct. 11, 2011 Christine K. Pierre, ... a "Professional Woman of the Year" by the National ... recognizes Pierre,s "outstanding leadership and commitment" within her profession, ... women. Pierre founded RxTrials, Inc., in 1994, ...
... Johnson (NYSE: JNJ ) will host a conference ... Tuesday, October 18, 2011, to review third-quarter results.  Dominic Caruso, ... Vice President, Investor Relations, will host the call. ... visiting the Company,s website at www.investor.jnj.com . ...
Cached Medicine Technology:Christine Pierre Selected as "Professional Woman of the Year" 2
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
Medicine Products: